INTRODUCTION: We hypothesized that the adverse event (AE) profile of cabazitaxel with regard to alopecia, nail changes, neuropathy, and dysgeusia differs from docetaxel.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
MATERIALS AND METHODS: Prospectively collected data on treatment-emergent AEs (frequency and grade [G]) from clinical trial databases of docetaxel every 3 weeks (q3w) (in TAX327 and VENICE) and cabazitaxel q3w (in TROPIC) were analyzed.
RESULTS: The frequency of new or worsening AEs (all G and G3-4) for 1301 patients was significantly less for alopecia, nail changes, neuropathy, and dysgeusia for cabazitaxel compared with docetaxel.
CONCLUSION: Treatment with cabazitaxel might cause less alopecia, nail changes, neuropathy, and dysgeusia compared with docetaxel.
Omlin A, Sartor O, Rothermundt C, Cathomas R, De Bono JS, Shen L, Su Z, Gillessen S. Are you the author?
Kantonsspital St Gallen, Department of Oncology and Hematology, St Gallen, Switzerland; Tulane University, Department of Medicine and Urology, New Orleans, LA; Division of Oncology/Hematology, Kantonsspital Graubünden, Chur, Switzerland; Prostate Cancer Targeted Therapies Group, Royal Marsden NHS Foundation Trust and Institute of Cancer Research, ICR, Sutton, UK; Sanofi-Aventis, Bridgewater, NJ.
Reference: Clin Genitourin Cancer. 2015 Jan 30. pii: S1558-7673(15)00012-9.